Inhibition of forkhead box O1 protects pancreatic beta-cells against dexamethasone-induced dysfunction

Area of Science:

• Endocrinology
• Molecular Biology
• Cell Biology

Background:

• Forkhead Box O1 (FoxO1) is a crucial transcription regulator in insulin/IGF-I signaling.
• Dexamethasone (DEX) is known to increase FoxO1 activity in various cell types.
• The precise role of FoxO1 in DEX-induced pancreatic beta-cell dysfunction remains unclear.

Purpose of the Study:

• To investigate if FoxO1 mediates DEX-induced pancreatic beta-cell dysfunction.
• To elucidate the underlying molecular mechanisms of DEX-induced beta-cell dysfunction involving FoxO1.
• To assess the therapeutic potential of FoxO1 inhibition in protecting beta-cells.

Main Methods:

• Utilized pancreatic beta-cell line RINm5F cells and primary rat islets.
• Assessed FoxO1 expression, phosphorylation, and activity following DEX treatment.
• Employed RNA interference to knock down FoxO1 expression.
• Evaluated the impact on pancreatic duodenal homeobox-1 (PDX1) expression and nuclear localization.
• Measured glucose-stimulated insulin secretion (GSIS) in rat islets.

Main Results:

• DEX significantly increased FoxO1 mRNA and protein levels while decreasing its phosphorylation via the Akt pathway.
• Activated FoxO1 led to the inhibition of PDX1 expression and its nuclear exclusion.
• Knockdown of FoxO1 reversed DEX-induced PDX1 downregulation and restored GSIS.
• FoxO1 activation was identified as a key mediator of DEX-induced beta-cell dysfunction.

Conclusions:

• FoxO1 plays an integral role in DEX-induced impairment of PDX1 expression and GSIS in pancreatic beta-cells.
• Inhibition of FoxO1 effectively protects pancreatic beta-cells against DEX-induced dysfunction.
• Targeting FoxO1 presents a potential therapeutic strategy for managing steroid-induced beta-cell damage.